Vertex Pharmaceuticals officer proposes $8.37M share sale

Available on EDGAR 11/12/2026 - 10:23 AM EST Accepted by SEC EDGAR 11/12/2026 - 10:23 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Vertex Pharmaceuticals Inc. (VRTX) officer Charles F. Wagner Jr. reported a proposed sale of 15,286 common shares, with an aggregate market value of $8,374,740.82 and an approximate sale date of November 12, 2026. The listed acquisition history includes ESPP purchases and restricted stock vesting dated from November 14, 2023, through May 14, 2025.

Key Figures

Proposed shares to be sold: 15,286 shares Aggregate market value: $8,374,740.82 Issuer shares outstanding: 253,537,674 shares +1 more

4 metrics

Proposed shares to be sold 15,286 shares Approximate sale date November 12, 2026

Aggregate market value $8,374,740.82 Proposed sale

Issuer shares outstanding 253,537,674 shares Number reported in the securities table

Plan adoption or instruction date August 10, 2026 Recorded if relying on Rule 10b5-1

Key Terms

Rule 10b5-1, ESPP Purchase, Restricted Stock Vesting

3 terms

Rule 10b5-1 regulatory

"if relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

ESPP Purchase financial

"Nature of Acquisition Transaction: ESPP Purchase"

Restricted Stock Vesting financial

"Nature of Acquisition Transaction: Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What plan date and broker are listed for Charles F. Wagner Jr.'s VRTX sale?

The notice records August 10, 2026 as the plan adoption or giving-of-instruction date if relying on Rule 10b5-1, and identifies Fidelity Brokerage Services LLC as broker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001223348
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	WAGNER CHARLES F JR
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	15286	8374740.82	253537674	11/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/14/2023	ESPP Purchase	Issuer			19	11/14/2023	Cash
Common	11/14/2024	ESPP Purchase	Issuer			15	11/14/2024	Cash
Common	02/20/2024	Restricted Stock Vesting	Issuer			221	02/20/2024	Compensation
Common	05/14/2024	ESPP Purchase	Issuer			54	05/14/2024	Cash
Common	02/10/2025	Restricted Stock Vesting	Issuer			3644	02/10/2025	Compensation
Common	02/17/2025	Restricted Stock Vesting	Issuer			2448	02/17/2025	Compensation
Common	02/24/2025	Restricted Stock Vesting	Issuer			3533	02/24/2025	Compensation
Common	02/26/2025	Restricted Stock Vesting	Issuer			5300	02/26/2025	Compensation
Common	05/14/2025	ESPP Purchase	Issuer			52	05/14/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Margaret Campbell, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Charles F. Wagner Jr
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)